Pfizer Secures $1.5 Billion Blackstone Backing to Advance Weight-Loss Drug Push
Pfizer has struck a financing agreement with Blackstone worth up to $1.5 billion to support development of its obesity-drug program, according to reports. The deal underscores how major pharmaceutical companies are increasingly leaning on private capital to help fund high-cost, high-risk drug pipelines as competition intensifies in the booming weight-loss market.
